Answers are grounded in this paper and cite their sources.
Plasma biomarkers for Alzheimer’s disease (AD) on fully automated platforms offer accessible, cost-effective diagnostic tools. Here we aimed to compare Lumipulse plasma phospho-tau217 (p-tau217) and the p-tau217/beta-amyloid42 ratio (p-tau217/Aβ 42 ) with regulatory-authorized cerebrospinal fluid (CSF) biomarkers (Aβ 42 /Aβ 40 and p-tau181/Aβ 42 ) for identifying AD pathology (Aβ-PET visual read) across a memory clinic ( n = 129), a primary care ( n = 220) and a research cohort ( n = 165). Regulatory-authorized cutoffs were used for the plasma and CSF biomarkers. Plasma biomarkers identified Aβ pathology with areas under the curve between 0.90 and 0.96. Using one cutoff, plasma p-tau217 (83–91%) and p-tau217/Aβ 42 (83–92%) had comparable accuracies to CSF (88–90%) across all cohorts (all P ≥ 0.05). With a two-cutoff approach, plasma p-tau217 (90–97%) remained comparable to CSF (91%) in the clinical cohorts (all P adj ≥ 0.12). Results with cohort-derived cutoffs are also provided. In conclusion, regulatory-authorized plasma p-tau217 and p-tau217/Aβ 42 demonstrated performance comparable to regulatory-authorized CSF tests for detecting Aβ pathology in symptomatic individuals.
No takes yet. Share an insight, caveat, or question.
Warmenhoven et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: